These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26243648)

  • 1. Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor.
    Hermanson TT; Hrushesky WJ; Knopf KB; Bennett CL
    J Oncol Pract; 2015 Sep; 11(5):363-4. PubMed ID: 26243648
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
    Greillier L; Tomasini P; Barlesi F
    Ther Adv Respir Dis; 2016 Oct; 10(5):485-91. PubMed ID: 27340254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
    Karayama M; Inui N; Kusagaya H; Suzuki S; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Suda T
    Cancer Chemother Pharmacol; 2016 May; 77(5):1011-8. PubMed ID: 27034279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
    Muto S; Takagi H; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
    Anticancer Res; 2017 Jun; 37(6):3169-3174. PubMed ID: 28551660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of Bevacizumab in Non-small Cell Lung Cancer].
    Xu P; Li H
    Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):272-277. PubMed ID: 28442017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.
    Carroll NM; Delate T; Menter A; Hornbrook MC; Kushi L; Aiello Bowles EJ; Loggers ET; Ritzwoller DP
    J Oncol Pract; 2015 Sep; 11(5):356-62. PubMed ID: 26060223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
    Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
    Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.
    Socinski MA; Chaft JE; Levy B; Riely GJ; Langer CJ; Perez-Soler R; Middleton DL; Gracie-King L; Healy LM
    Clin Lung Cancer; 2017 May; 18(3):255-258. PubMed ID: 28188100
    [No Abstract]   [Full Text] [Related]  

  • 10. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
    Goto K; Endo M; Kusumoto M; Yamamoto N; Ohe Y; Shimizu A; Fukuoka M
    Cancer Sci; 2016 Dec; 107(12):1837-1842. PubMed ID: 27714941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing.
    Snee M
    Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):468-72. PubMed ID: 24909702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in lung cancer: hurdles in clinical development.
    Pirker R
    Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How should we use bevacizumab in patients with non-small cell lung cancer?
    Kim YH; Mishima M
    J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996
    [No Abstract]   [Full Text] [Related]  

  • 15. (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
    Chen B; Zhao G; Ma Q; Ji B; Ji T; Xin H; Gao S
    Int J Clin Exp Pathol; 2015; 8(12):16064-72. PubMed ID: 26884883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey.
    Velcheti V; Viswanathan A; Govindan R
    J Thorac Oncol; 2006 Jun; 1(5):501. PubMed ID: 17409907
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
    Chen J; Lu Y; Zheng Y
    Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
    D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
    J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
    [No Abstract]   [Full Text] [Related]  

  • 19. Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
    Sudo K; Sato K; Sakamoto S; Hasegawa Y; Asano M; Okuda Y; Takeda M; Sano M; Watanabe H; Shioya T; Ito H
    Anticancer Res; 2017 Oct; 37(10):5565-5571. PubMed ID: 28982871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
    Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
    J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.